Immunotherapy in Thailand Your guide to cost, top specialists & hospitals

Our partner hospitals run dedicated medical oncology departments with tumour profiling laboratories, infusion suites, and full emergency support. Leading JCI-accredited international hospitals in Bangkok have extensive experience delivering immunotherapy to international patients, with pharmacies that stock the full range of approved checkpoint inhibitors.

Our partner oncologists hold board certification in medical oncology with subspecialty training in immunotherapy protocols. Many trained at international cancer centres and bring that experience to managing immune-related adverse events, the clinical skill that distinguishes good immunotherapy care from adequate care.

Confirm board certification in medical oncology and specific experience with checkpoint inhibitors for your cancer type. Ask how they monitor for immune-related adverse events and what protocols they follow if complications arise. An oncologist who provides a written treatment plan and explains biomarker results clearly is meeting the standard you should expect.

Response rates vary by cancer type and biomarker status. In PD-L1-high non-small cell lung cancer, pembrolizumab can improve survival compared with chemotherapy, though not every patient responds.⁵ Advanced melanoma treated with combination checkpoint therapy can produce durable responses that continue long after treatment in some patients, though not everyone responds.⁴ Not every patient responds, which is why biomarker selection matters.

Imaging assessment after every two to four cycles shows whether the tumour is responding. Durable responses lasting months to years are possible even after treatment stops. Pseudoprogression can occur, so early scans require careful interpretation by an experienced oncologist.

A single cycle of checkpoint inhibitor therapy in Thailand typically costs between $3,000 and $5,400, depending on the drug, dosing protocol, and whether combination therapy is used. This compares favourably to equivalent treatment in the US, UK, and Australia.

The immunotherapy drug itself is the largest cost component. Oncologist consultation and treatment-planning fees cover clinical oversight. Infusion-suite charges cover administration and nursing supervision. Biomarker testing, blood monitoring, and coordinator support are included in the package.

The specific drug and dosing weight are the main cost drivers. Combination regimens using two checkpoint inhibitors cost more per cycle. The number of cycles varies; some patients respond after four to six cycles, while others continue for up to two years.

Typical per-cycle ranges at our partner hospitals:

• Single-agent PD-1/PD-L1 inhibitor: $3,000–$4,200 for standard checkpoint blockade
• CTLA-4 inhibitor monotherapy: $3,500–$4,800 typically used in melanoma protocols
• Combination checkpoint therapy: $4,500–$5,400 for dual blockade in eligible patients

Final pricing is confirmed after your oncologist reviews your pathology and recommends a protocol.

Immunotherapy in Thailand costs 50 to 70 percent less than equivalent treatment in the US ($9,000–$18,000 per cycle), Australia (A$7,500–A$15,000), and UK (£6,600–£13,500). Over a multi-cycle course, the cumulative savings make treatment accessible to patients who face cost barriers at home.

In many cases, yes. Cycle intervals of two to six weeks allow time for travel. Your oncologist advises based on your response and side-effect profile. Carrying a treatment summary and having blood work done locally between visits is recommended.

Routine blood tests at every cycle screen for thyroid, liver, kidney, and adrenal inflammation. Skin rashes, colitis, and pneumonitis are monitored clinically. Most immune-related events are mild and respond well to corticosteroids when caught early. Severe events are managed under close medical supervision with immunosuppressive therapy.

Response is assessed through imaging scans, typically CT or PET-CT, after every two to four cycles. Some patients experience pseudoprogression where tumours appear larger initially before shrinking. Your oncologist interprets scan results in context and explains what to expect at each review.

Yes. Immunotherapy at JCI-accredited hospitals in Thailand follows the same international protocols and monitoring standards as leading Western cancer centres. The drugs are identical, and the oncology teams have specific experience managing immune-related adverse events.

Comprehensive biomarker testing before treatment ensures you receive the right drug. Routine blood work at every cycle catches organ inflammation early. Patients with pre-existing autoimmune conditions require careful assessment. Following your oncologist's monitoring schedule is the single most important safety measure.

Grade 3 or 4 immune-related adverse events typically require a treatment pause and corticosteroid management. Your oncologist decides whether to resume, switch agents, or discontinue based on the severity and your overall response. These decisions follow established international oncology guidelines.

Plan for 7 to 14 days per cycle, covering biomarker testing or review, pre-infusion blood work, the infusion, post-infusion monitoring, and a follow-up assessment. If completing a full course, stays of several months may be needed. Many patients return for cycles at intervals.

Your care coordinator handles all scheduling. The quote covers oncologist consultations, the immunotherapy drug, infusion-suite use, biomarker testing, blood monitoring, supportive medications, and coordinator support. Accommodation and flights are arranged separately.

We provide detailed treatment summaries, drug protocols, biomarker results, and monitoring plans for your home medical team. If further cycles are administered locally, your home oncologist can continue without interruption using our documentation. Remote consultations with your Thai oncologist are available.